Glasdegib with Low-Dose Cytarabine: A New Upfront Option for the Vulnerable AML Patient.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31324656.
- Also identified by DOI 10.1158/1078-0432.CCR-19-1986.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A multitude of regulatory approvals has recently changed the therapeutic landscape of acute myeloid leukemia. Among these was upfront therapy with the Hedgehog inhibitor glasdegib with low-dose cytarabine. Understanding the process of and rationale for approval of this promising combination is timely and valuable for the oncology community.<i>See related article by Norsworthy et al., p. 6021</i>.
Medical subject headings
- Hedgehog Proteins
- Leukemia, Myeloid, Acute